Biomarker Discovery Outsourcing Services Market Report 2026

Biomarker Discovery Outsourcing Services Market Overview

• Biomarker Discovery Outsourcing Services market size has reached to $16.96 billion in 2025 • Expected to grow to $33.94 billion in 2030 at a compound annual growth rate (CAGR) of 14.5% • Growth Driver: Personalized Medicine Driving Growth In Biomarker Discovery Outsourcing • Market Trend: Advanced Technologies Driving Innovation In The Biomarker Discovery Outsourcing Services Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biomarker Discovery Outsourcing Services Market?

Biomarker discovery outsourcing services refer to specialized services provided by external organizations or companies that assist in identifying, validating, and developing biomarkers. These services facilitate the advancement of personalized medicine by enabling the identification of biological markers that can guide diagnosis, prognosis, and therapeutic decisions tailored to individual patients. The main types of biomarker discovery outsourcing services are predictive biomarkers, prognostic biomarkers, safety biomarkers, and surrogate endpoints. Predictive biomarkers are biological indicators used to identify which patients are likely to benefit from a specific therapeutic intervention. The discovery phases are categorized into biomarker identification, biomarker validation, biomarker profiling, biomarker panel development, and biomarker selection used for therapeutic areas such as oncology, cardiology, neurology, autoimmune diseases, and others. End users, such as pharmaceutical companies and biotechnology companies.

What Is The Biomarker Discovery Outsourcing Services Market Growth Forecast?

The biomarker discovery outsourcing services market size is expected to see rapid growth in the next few years. It will grow to $33.94 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising demand for early disease detection tools, expansion of biomarker-driven clinical trials, growing use of ai-enabled biomarker analytics, increasing regulatory acceptance of biomarker endpoints. Major trends in the forecast period include increasing adoption of multi-omics biomarker platforms, rising demand for predictive and prognostic biomarkers, growing use of outsourced biomarker validation services, expansion of companion diagnostics development, enhanced focus on clinical trial biomarker integration.

Global Biomarker Discovery Outsourcing Services Market Segmentation

1) By Type: Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers, Surrogate Endpoints 2) By Discovery Phase: Biomarker Identification, Biomarker Validation, Biomarker Profiling, Biomarker Panel Development, Biomarker Selection 3) By Therapeutic Area: Oncology, Cardiology, Neurology, Autoimmune Diseases, Other Therapeutic Areas 4) By End Use: Pharmaceutical Companies, Biotechnology Companies Subsegments: 1) By Predictive Biomarkers: Disease Risk Assessment, Therapy Response Prediction, Personalized Medicine Guidance 2) By Prognostic Biomarkers: Disease Progression Prediction, Patient Survival Forecast, Recurrence Risk Assessment 3) By Safety Biomarkers: Toxicity Prediction, Drug Safety Evaluation, Adverse Effect Risk Assessment 4) By Surrogate Endpoints: Clinical Trial Outcome Indicators, Disease Progression Monitoring, Therapy Efficacy Tracking

What Is The Driver Of The Biomarker Discovery Outsourcing Services Market?

The rising focus on personalized medicine is expected to propel the growth of the biomarker discovery outsourcing services market going forward. Personalized medicine refers to healthcare that tailors medical treatment to the individual characteristics of each patient. The rise of personalized medicine is due to individual genetic, lifestyle, and environmental factors, resulting in precise healthcare outcomes that ultimately improve patient care and reduce adverse effects. Outsourcing biomarker discovery services facilitates the advancement of personalized medicine by providing tailored diagnostic and therapeutic solutions based on individual patients' biological markers. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition, a US-based organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023, include seven cancer drugs and three for other diseases and conditions. Therefore, the increasing focus on personalized medicine drives the growth of the biomarker discovery outsourcing services.

Key Players In The Global Biomarker Discovery Outsourcing Services Market

Major companies operating in the biomarker discovery outsourcing services market are Charles River Laboratories International Inc, Evotec SE, WuXi AppTec Co. Ltd, Precision for Medicine Inc, SomaLogic Inc, Metabolon Inc, Caprion Proteomics Inc, Crown Bioscience Inc, Selvita S.A., Frontage Laboratories Inc, BioAgilytix Labs LLC, Discovery Life Sciences LLC, Labcorp Drug Development Inc, Parexel International Corporation, ICON plc, Medpace Inc, Syneos Health Inc, Celerion Inc, Canopy Biosciences LLC, BioIVT LLC, Intertek Group plc, Eurofins Scientific SE

Global Biomarker Discovery Outsourcing Services Market Trends and Insights

Major companies operating in the biomarker discovery outsourcing services market are focusing on developing multiplexed biomarker assays, such as the immunoproteomic discovery platform, to improve patient outcomes and advance the field of discovering biomarkers. An immunoproteomic discovery platform is a specialized system that combines immunology and proteomics to identify and analyze proteins related to the immune response. For instance, in October 2023, Sengenics Corporation LLC, a Singapore-based precision medicine company, launched the immunoproteomic discovery platform, a comprehensive protein microarray platform for analyzing autoantibodies associated with disease diagnosis and therapeutic intervention. The i-Ome Discovery platform was developed to advance immune biomarker discovery and development and support academic and clinical biopharmaceutical research teams seeking to better understand the dynamic interactions and relationships between proteins, the immune system, and disease.

What Are Latest Mergers And Acquisitions In The Biomarker Discovery Outsourcing Services Market?

In March 2025, Momentum Biotechnologies, a US-based contract research organization specializing in mass spectrometry-based drug discovery, acquired OmicScouts GmbH for an undisclosed amount. With this acquisition, Momentum aims to expand its portfolio of well-validated proteomic assays, accelerate target engagement and biomarker discovery workflows, and extend its geographic presence into Europe. OmicScouts GmbH is a Germany based CRO focused on mass spectrometry–based proteomics, chemoproteomics, and biomarker research, providing system-wide assays for target identification, drug response biomarkers, and mechanism-of-action studies.

Regional Outlook

North America was the largest region in the biomarker discovery outsourcing services market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biomarker Discovery Outsourcing Services Market?

The biomarker discovery outsourcing services market includes revenues earned by entities through validation and verification studies, clinical sample analysis, bioinformatics, and data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biomarker Discovery Outsourcing Services Market Report 2026?

The biomarker discovery outsourcing services market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biomarker discovery outsourcing services industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.